Related Experiment Videos

Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis

Insights

Decision analysis suggests aortocoronary bypass surgery is superior to medical management for most coronary artery disease patients. The procedure offers improved quality-adjusted life expectancy, even for those with less severe disease.

Area of Science:

  • Cardiology
  • Decision Analysis
  • Health Economics

Background:

  • Coronary artery disease (CAD) presents complex treatment choices between surgical intervention and medical management.
  • Evaluating these options requires integrating clinical data with patient preferences for survival and quality of life.

Purpose of the Study:

  • To utilize decision-analytic techniques to compare aortocoronary bypass surgery with medical management for hypothetical CAD patients.
  • To quantify treatment benefits in terms of quality-adjusted life expectancy.

Main Methods:

  • A decision framework was developed incorporating key variables affecting treatment choice.
  • Probability estimates were sourced from expert cardiologists and cardiac surgeons.
  • Patient preferences were elicited using utility values for different health outcomes, including angina severity and survival duration.

Main Results:

  • Decision analysis favored aortocoronary bypass surgery for 13 out of 14 hypothetical patients, including those with one- and two-vessel disease.
  • Medical management was preferred only for a patient with mild angina, severe left ventricular dysfunction, and a generally poor prognosis.
  • Results were sensitive to long-term survival probabilities but not operative mortality rates.

Conclusions:

  • Aortocoronary bypass surgery is generally favored over medical management for coronary artery disease patients when considering quality-adjusted life expectancy.
  • Discrepancies between clinical judgment and decision analysis highlight the need for structured decision-making tools.
  • Cost-effectiveness analysis indicates significant value for surgery, with costs per quality-adjusted year of life gained ranging from $1,500 to $32,000.

Related Concept Videos